Invion AI Stock Analysis
Want to see AU:IVX full AI Analyst Report?
Invion (IVX) AI Stock Analysis
Invion
(ASX:IVX)
The overall score is very low, driven primarily by the company's dire financial performance, marked by persistent cash burn and deep losses that overshadow a minimal return to revenue. This is compounded by a bearish technical trend with the stock price below all key moving averages, and a negative P/E ratio that underscores the lack of current profitability. The company's financial trajectory remains a significant concern.
Invion (IVX) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 4.08M
- Dividend Yield
- ―
- Average Volume (3M)
- 100.99K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- -0.42
- Revenue Growth
- ―
- EPS Growth
- 48.77%
- Country
- Australia
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Invion Business Overview & Revenue Model
Company Description
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being...
Invion Financial Statement Overview
Summary
Financial health is critically weak. The company has returned to minimal revenue ($385K) but suffers from deep net losses (-$5.6M), severe and persistent negative free cash flow (-$2.38M), and a rapidly eroding equity base. The introduction of new debt adds risk to an already unsustainable operational profile.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
15Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 384.71K | 385.32K | 0 | 3.69M | 4.10M | 3.29M |
| Gross Profit | -1.34M | 385.32K | -1.29M | 1.00M | 1.21M | 969.12K |
| EBITDA | -3.94M | -3.94M | -4.00M | -4.57M | -965.37K | -1.82M |
| Net Income | -5.63M | -5.63M | -8.81M | -5.63M | -1.61M | -2.24M |
Balance Sheet | ||||||
| Total Assets | 8.17M | 8.17M | 9.49M | 15.45M | 19.05M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 592.31K | 592.31K | 850.37K | 783.53K | 4.08M | 8.47M |
| Total Debt | 1.55M | 1.55M | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.85M | 2.85M | 1.24M | 1.01M | 650.63K | 462.41K |
| Stockholders Equity | 5.32M | 5.32M | 8.25M | 14.44M | 18.40M | 19.58M |
Cash Flow | ||||||
| Free Cash Flow | -2.38M | -2.38M | -2.97M | -3.30M | -4.39M | -8.36M |
| Operating Cash Flow | -2.37M | -2.37M | -2.97M | -2.40M | -1.81M | -1.11M |
| Investing Cash Flow | -68.83K | -68.83K | 0 | -900.00K | -2.58M | -7.25M |
| Financing Cash Flow | 2.18M | 2.18M | 3.04M | 0 | 15.80M | 15.80M |
Invion Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IVX, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 42.58 is Neutral, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IVX.
Invion Peers Comparison
Overall Rating
AU:MVP57Neutral
AU:PER45Neutral
AU:PKP39Underperform- AU:IVX38Underperform
AU:RGT37Underperform
AU:IDT34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:MVP | 57Neutral | AUD 48.44M | 76.78 | 1.13% | ― | 8.99% | 450.00% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:PER | 45Neutral | AUD 6.94M | -0.73 | -65.33% | ― | ― | 72.60% |
| AU:PKP | 39Underperform | AUD 18.75M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
| AU:IVX | 38Underperform | AUD 3.65M | -0.53 | -102.18% | ― | ― | 48.77% |
| AU:RGT | 37Underperform | AUD 2.48M | -0.20 | 102.60% | ― | 17.56% | 75.11% |
| AU:IDT | 34Underperform | AUD 14.06M | -5.31 | -13.81% | ― | 5.93% | 66.32% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:IVX | Invion Ltd. | 0.03 | -0.04 | -56.58% | |
| AU:PER | Percheron Therapeutics Limited | ― | ― | ― | |
| AU:RGT | Argent Biopharma Ltd | 0.02 | -0.06 | -74.39% | |
| AU:MVP | Medical Developments International Limited | 0.43 | -0.13 | -23.21% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.01 | -0.01 | -30.00% | |
| AU:IDT | IDT Australia Limited | 0.03 | -0.02 | -41.38% |
Invion Corporate Events
Invion Announces Philip Wood Board Appointment and Company Secretary Change
Invion is an ASX-listed life-science company researching and developing Photosoft technology for treatments spanning cancers, ophthalmic diseases and infectious diseases. It holds the global exclusive licence to the technology for multiple cancer and...
Invion secures major funding as Photosoft cancer trial advances to Phase II
Invion has completed patient treatment and closed recruitment for its Phase I non-melanoma skin cancer trial using its Photosoft platform, with preliminary data from 14 patients showing no treatment-related adverse events or dose-limiting toxicities...
Invion Moves to Fully Virtual AGM and Paperless Meeting Materials
Invion Limited has scheduled its Annual General Meeting of shareholders to be held virtually on 25 November 2026 at 1:00pm AEDT, using online webinar technology that allows investors to attend remotely, ask questions and vote in real time. Shareholde...
Invion Plans New Share and Option Issue in ASX Placement
Invion Limited has lodged a notice with the ASX outlining a proposed issue of new securities via a placement or similar capital-raising mechanism. The company plans to issue up to 1,374,003 ordinary fully paid shares under code IVX and 11,055,313 opt...
Invion secures financing to cover up to 85% of clinical trial costs
Invion has secured two complementary financing arrangements that are expected to cover up to about 85% of its current and future clinical trial costs, including ongoing non-melanoma skin cancer and upcoming anogenital cancer trials. The structure is...
Invion and Percheron Align on Novel Cancer Combination Using Photosoft and VISTA Immunotherapy
Invion has entered a non-exclusive preclinical research collaboration with fellow ASX-listed biotech Percheron Therapeutics to assess the combination of Percheron’s anti-VISTA monoclonal antibody HMBD-002 and Invion’s Photosoft INV043 photodynamic th...
Percheron and Invion pair VISTA immunotherapy with Photosoft cancer PDT
Percheron Therapeutics and Invion have entered a preclinical research collaboration to test Percheron’s anti-VISTA monoclonal antibody HMBD-002 with Invion’s Photosoft-based photodynamic therapy, INV043, in solid tumours. The partners aim to harness...
Invion Advances Photosoft-Based Skin Cancer Therapy After Strong Phase I Safety Readouts
Invion has closed patient recruitment and completed treatments in its Phase I non-melanoma skin cancer trial of investigational therapy INV043, reporting strong safety outcomes across 14 patients, including no serious adverse events, dose-limiting to...
Invion Plans ASX Share Placement to Boost Capital
Invion Limited has notified the ASX of a proposed placement involving up to 8,218,000 ordinary fully paid shares. The new securities are expected to be issued on Dec. 4, 2026, and will be quoted on the ASX subject to compliance with listing rules.The...
Invion Secures $400,000 in Director Loans to Support Working Capital
Invion has secured short-term funding support from two board members through unsecured director loans totaling $400,000 to bolster working capital. Executive Chair and CEO Prof Thian Chew and Non-Executive Director Alan Yamashita have each committed...
Invion Sets Out 2026 Governance Framework and Board Changes
Invion has detailed its corporate governance practices for the financial year ended 30 June 2026, outlining the composition of its four-member Board and recent changes, including the resignation of a non-executive director and the appointment of Paul...
Invion Narrows Annual Loss but Net Tangible Assets Slide Deeper Into Negative Territory
Invion Limited reported revenue of $384,707 for the year ended 30 June 2026 and a reduced net loss of $5.63 million, down 36% from the prior year, with no dividends declared. Despite the improved bottom line, net tangible assets per share fell furthe...
Invion Appoints New Director With No Current Securities Interests
Invion Limited has appointed Paul Hilton Field as a director effective 18 August 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Field currently holds no relevant interests in Invion securities a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026